BioPharma Drive: Drug Pricing

JUNE 26, 2025

The company has had a good deal of success with Jakafi, a multipurpose drug approved to treat rare blood cancers and graft-versus-host disease. But Jakafi’s main patents expire in 2028, a date that for years now has been on investors’ radar as they’ve pressed Incyte on what it expects will take the drug’s place.

Licensing 117

Licensing Licensing Therapies Vaccine 117

Alta Sciences

AUGUST 29, 2024

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning. billion USD by 2028. billion USD in 2023 to $166.53

Drug Development 52

Drug Development Clinical Trials Small Molecule Drugs 52

Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. Panel members flagged potential issues with variability between providers.

FDA 40

FDA Trials Therapies Regulations 40

Agency IQ

FEBRUARY 2, 2024

There are also continued questions about regulatory capacity and what the field will look like going forward, with implications for drug developers who rely on diagnostic products. A sea change for lab tests, the implications for drug developers and outstanding questions about endpoints In the U.S.,

FDA 40

FDA Laboratories Regulations Production 40

DrugBank

AUGUST 9, 2024

Moreover, the probability of success for a drug candidate entering clinical trials is only around 10%, highlighting the substantial risks involved. This high attrition rate directly results from the scientific and regulatory hurdles that drug candidates must overcome. trillion by 2028.

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

Codon

SEPTEMBER 29, 2024

2028 Over the next year, the scientific community ferociously interrogated the model. The average pass rate of phase I trials went up by 5 percent. It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. The next model of life had officially been released.

Engineering 145

Engineering Virus DNA Therapies 145